Cartesian Therapeutics Inc
RNAC
NASDAQ
Biotechnology
$8.84
USD
+0.12 (+1.38%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $267.91M
Volume 86.4K
Revenue
$1.48M
TTM
-17.3%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-151.89M
TTM
-318.9%
YoY
Operating Cash Flow
$-76.53M
TTM
-125.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.3 | 0.5 | 0.9 | 0.1 | 0.0 |
YoY Growth | -99.1% | +16.8% | — | -92.9% | -100.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.3 | 0.5 | 0.9 | 0.1 | 0.0 |
Selling, General & Administrative | 7.2 | 7.7 | 8.2 | 7.1 | 8.7 |
Other Operating Expenses | 0.0 | 0.0 | 56.7 | 0.0 | 0.0 |
Total Operating Expenses | 22.1 | 21.5 | 79.6 | 26.6 | 29.2 |
Operating Income | -21.8 | -21.1 | -78.6 | -26.5 | -29.2 |
EBITDA | -21.2 | -20.5 | -21.3 | -25.9 | -28.4 |
Other Income / Expense | 35.9 | -16.4 | -24.4 | -13.7 | 44.7 |
Total Other Income / Expense | 37.7 | -14.8 | -23.1 | -12.7 | 44.9 |
Income Before Income Taxes | 15.9 | -35.9 | -101.8 | -39.2 | 15.8 |
Income Taxes | 0.0 | 0.0 | -9.2 | 0.0 | 0.0 |
Net Income | 15.9 | -35.9 | -92.6 | -39.2 | 15.8 |
Consolidated Net Income / Loss | 15.9 | -35.9 | -92.6 | -39.2 | 15.8 |
Net Income Attributable to Common Shareholders | 13.3 | -35.9 | -92.6 | -39.2 | 13.7 |
Basic EPS | $0.51 | -$1.38 | -$3.56 | -$1.46 | $0.47 |
Diluted EPS | $0.50 | -$1.38 | -$3.62 | -$1.46 | $0.46 |
Basic Shares Outstanding | 26.0M | 26.0M | 26.0M | 26.9M | 29.5M |
Diluted Shares Outstanding | 26.4M | 26.0M | 25.5M | 26.9M | 29.9M |